Furthermore, we determined the proportion of both total and activated/PD-1+ [12] CD8+ T cells in the tumour at day 5 after treatment initiation, when tumours from mice treated with ATO plus aPD-L1 already display a significant tumour size decrease as compared with the other treatments, but no tumour has experienced complete regression yet (Fig. 2E). This evidence concerns the gene CD8A and neoplasm.